ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for patients with cancers that have unmet medical needs. Its lead development candidate is firmonertinib, a tyrosine kinase inhibitor being evaluated in multiple clinical trials for non-small cell lung cancer (NSCLC), including a Phase 3 trial for patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, and Phase 1b trials for NSCLC patients with activating EGFRm mutations, including PACC mutations and classical EGFRm. The company is also developing ARR-217, an antibody drug conjugate for gastrointestinal cancers, and other candidates (ARR-002, ARR-421, ARR-173) for solid tumors.

ArriVent BioPharma, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol AVBP. The company's shares are traded in US Dollars (USD), as it is headquartered in the United States and its primary listing is on a US exchange.

ArriVent BioPharma operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on developing targeted therapies for cancer, leveraging biotechnology to address specific genetic mutations and unmet medical needs in oncology.

ArriVent BioPharma is headquartered in Newtown Square, Pennsylvania, United States. The company serves global markets, with a focus on developing treatments for cancers that affect patients worldwide. Its clinical trials and strategic collaborations involve partners in the US, China, and other regions, indicating a broad international reach in its research and development efforts.

ArriVent BioPharma has strategic collaborations with several companies to advance its pipeline. These include Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. Its pipeline includes firmonertinib (lead candidate for NSCLC), ARR-217 (ADC for gastrointestinal cancers), and early-stage candidates ARR-002, ARR-421, and ARR-173 for solid tumors. The company's business model involves developing these candidates through clinical trials and, upon approval, commercializing them to generate revenue.